EUVIMEDEUVIMED entdecken
Crossref

Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study

Giacomo d'Andrea, Andrea Miuli, Mauro Pettorruso, Clara Cavallotto, Carlotta Marrangone, Alessio Cocco, Sergio De Filippis, Vassillis Martiadis, Ileana Andriola, Stefano Barlati, Antonio Vita, Bernardo Maria Dell'Osso und 3 weitere

Journal of Affective Disorders · 2024-12 · 367 · 583-588

DOI: 10.1016/j.jad.2024.09.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Affective Disorders, 2024-12. Verfasst von Giacomo d'Andrea und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.; Department of Mental Health, ASL 02…. Hauptthemen laut MEDLINE: Vortioxetine, Administration, Intranasal, Drug Therapy, Combination, Ketamine. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment-Resistant Depression (TRD) affects almost 30 % of patients with Major Depressive Disorder (MDD). Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD in combination with a Serotonin Specific Reuptake Inhibitor/SSRI or a Serotonin-Norepinephrine Reuptake Inhibitor/SNRI. There is a lack of studies investigating the effectiveness and safety of ESK-NS in combination with other oral antidepressants. AIM: To assess the efficacy of Vortioxetine plus ESK-NS in mitigating depressive symptoms and emotional blunting, as well as its tolerability in TRD subjects, compared to the standard-of-care of SSRI/SNRI plus ESK-NS. METHODS: We conducted a post-hoc analysis of the REAL-ESK study. The study included twenty TRD patients, ten subjects taking Vortioxetine as the main oral antidepressant with ESK-NS, and ten subjects taking SSRI or SNRI with ESK-NS. Psychometric assessments (Montgomery-Åsberg Depression Rating Scale/MADRS, Brief Psychiatric Rating Scale/BPRS) were conducted at baseline(T0), one month(T1), and three months after the treatment initiation(T2). RESULTS: The combination of Vortioxetine and ESK-NS was as effective as the standard-of-care in reducing depressive symptoms, with a higher effect size in reducing emotional blunting at T2. The safety and tolerability profile of the Vortioxetine+ESK-NS combination appeared to be better, with a lower rate of treatment-emergent adverse events. CONCLUSION: The combination of Vortioxetine and ESK-NS may be a valuable alternative to the standard-of-care SSRI/SNRI plus ESK-NS in TRD patients, particularly regarding the reduction of emotional blunting and potentially a better safety and tolerability profile. Further randomized controlled trials with larger sample sizes and prospective designs are needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VortioxetineAdministration, IntranasalDrug Therapy, CombinationKetamineSelective Serotonin Reuptake InhibitorsDepressive Disorder, Treatment-ResistantAntidepressive AgentsMajor Depressive DisorderHumansMaleFemaleAdultMiddle AgedPsychiatric Status Rating ScalesTreatment OutcomeSerotonin and Noradrenaline Reuptake Inhibitors

Stichwörter der Autor:innen

DepressionESK-NSEmotional bluntingGlutamateTRDVortioxetine

Substanzen

VortioxetineKetamineSelective Serotonin Reuptake InhibitorsEsketamineAntidepressive AgentsSerotonin and Noradrenaline Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.; Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.
  • Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.. Electronic address: andreamiuli@live.it.
  • Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti, Italy.
  • Department of Mental Health, ASL 02 Lanciano-Vasto-Chieti, Chieti, Italy.
  • Department of Neuropsychiatry, Villa Von Siebenthal Neuropsychiatric Clinic, Genzano di Roma, Italy.
  • ASL Napoli 1 Centro, Department of Mental Health, Napoli, Italy.

Zitieren

APA

d'Andrea, G., Miuli, A., Pettorruso, M., Cavallotto, C., Marrangone, C., Cocco, A., De Filippis, S., Martiadis, V., Andriola, I., Barlati, S., Vita, A., Dell'Osso, B. M., Sensi, S. L., Di Lorenzo, G., & Martinotti, G. (2024). Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study. Journal of Affective Disorders, 367, 583-588. https://doi.org/10.1016/j.jad.2024.09.004

Vancouver

d'Andrea G, Miuli A, Pettorruso M, Cavallotto C, Marrangone C, Cocco A, et al. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study. Journal of Affective Disorders. 2024;367:583-588. doi:10.1016/j.jad.2024.09.004

BibTeX
@article{dAndrea2024,
  author = {d'Andrea, Giacomo and Miuli, Andrea and Pettorruso, Mauro and Cavallotto, Clara and Marrangone, Carlotta and Cocco, Alessio and De Filippis, Sergio and Martiadis, Vassillis and Andriola, Ileana and Barlati, Stefano and Vita, Antonio and Dell'Osso, Bernardo Maria and Sensi, Stefano L and Di Lorenzo, Giorgio and Martinotti, Giovanni},
  title = {Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study},
  journal = {Journal of Affective Disorders},
  year = {2024},
  volume = {367},
  pages = {583--588},
  doi = {10.1016/j.jad.2024.09.004}
}
Kostenlos starten →